title: Effects of new inotropic agents on exercise performance.
abstract: Symptoms of dyspnea and fatigue limit effort tolerance in patients with chronic cardiac failure. These symptoms may be consequent to an abnormal cardiocirculatory response to the increased O2 demand that accompanies exercise as manifested by: reduced ability to augment cardiac output in response to increased left ventricular filling pressure, inadequate vasodilatory response in exercising limbs, the onset of lactate production by muscle at relatively low levels of work, and increased work of breathing that accompanies pulmonary venous hypertension and abnormal compliance of the lung secondary to left ventricular dysfunction. The clinical experience with new positive inotropic agents in the long-term treatment of patients with chronic cardiac failure is accumulating rapidly. Attention has focused on the ability of these agents to improve exercise performance, particularly their ability to increase the aerobic capacity. The experience to date suggest that beta-adrenergic receptor agonists offer little advantage in this regard while causing ventricular arrhythmias. On the other hand, the phosphodiesterase inhibitors, MDL 17,043 and MDL 19,205, and the bipyridine derivatives, amrinone and milrinone, may improve exercise performance in many patients and exert a sustained effect during long-term therapy. Placebo-controlled, randomized trials will need to be performed, however, to determine the ultimate efficacy and safety of these agents. The most meaningful results for analysis will be obtained when objective parameters of exercise performance, such as aerobic capacity and anaerobic threshold, are monitored that are free of patient or physician bias.
authors.forename: K T
authors.initials: KT
authors.lastname: Weber
authors.forename: J S
authors.initials: JS
authors.lastname: Janicki
authors.forename: C S
authors.initials: CS
authors.lastname: Maskin
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000631:Aminopyridines / Q000494:pharmacology; D000676:Amrinone; D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002908:Chronic Disease; D017335:Enoximone; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D020105:Milrinone; D009132:Muscles / Q000098:blood supply; D010100:Oxygen / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion / Q000187:drug effects*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D011728:Pyridones / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000318:Adrenergic beta-Agonists; D000631:Aminopyridines; D002316:Cardiotonic Agents; D007093:Imidazoles; D011728:Pyridones; C039686:piroximone; D017335:Enoximone; D020105:Milrinone; D000676:Amrinone; D010100:Oxygen